References
- Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011 [cited 2017 Jul 11];364:1046–1060. Internet.
- American Cancer Society. About multiple myeloma [Internet]. [cited 2018 Sep 4]. Available from: https://www.cancer.org/cancer/multiple-myeloma/about.html.
- Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128. [cited 2017 Sep 6]. Internet
- D’Agostino M, Boccadoro M, Smith EL. Novel immunotherapies for multiple myeloma. Curr Hematol Malig Rep. Internet. 2017 [cited 2018 Sep 4];12:344–357. Available at http://www.ncbi.nlm.nih.gov/pubmed/28819882
- Gay F, D’Agostino M, Giaccone L, et al. Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors. Clin Lymphoma Myeloma Leuk. Internet. 2017 [cited 2018 Sep 4];17:471–478. Available at http://www.ncbi.nlm.nih.gov/pubmed/28689001
- D’Agostino M, Gazzera G, Cetani G, et al. Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma. Curr Med Chem. Internet 2018 [cited 2018 Sep 4];25: Available at http://www.ncbi.nlm.nih.gov/pubmed/29756564
- van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. Internet. 2018 [cited 2017 Dec 14];131:13–29. Available at http://www.ncbi.nlm.nih.gov/pubmed/29118010
- Reinherz EL, Kung PC, Goldstein G, et al. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci U S A. Internet. 1980 [cited 2018 May 9];77:1588–1592. Available at http://www.ncbi.nlm.nih.gov/pubmed/6966400
- Nakagawara K, Mori M, Takasawa S, et al. Assignment of CD38, the gene encoding human leukocyte antigen CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase), to chromosome 4p15. Cytogenet Genome Res. Internet. 1995 [cited 2018 Sep 4];69:38–39. Available at http://www.ncbi.nlm.nih.gov/pubmed/7835083
- Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. Internet. 2001 [cited 2017 Dec 14];25:1–12. Available at http://www.sciencedirect.com/science/article/pii/S014521260000093X
- Leo R, Boeker M, Peest D, et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol. 1992;64:132–139. [cited 2018 Sep 4]. Internet
- Costa F, Toscani D, Chillemi A, et al. Expression of CD38 in myeloma bone niche: a rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation. Oncotarget. Internet. 2017 [cited 2018 Sep 4];8:56598–56611. Available at http://www.ncbi.nlm.nih.gov/pubmed/28915615
- Atanackovic D, Steinbach M, Radhakrishnan SV, et al. Immunotherapies targeting CD38 in multiple myeloma. Oncoimmunology. Internet. 2016 [cited 2018 Sep 4];5:e1217374. Available at http://www.ncbi.nlm.nih.gov/pubmed/27999737
- Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. Internet. 2016 [cited 2018 Sep 4];128:384–394. Available at http://www.ncbi.nlm.nih.gov/pubmed/27222480
- Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008;88:841–886. [cited 2018 Sep 4]. Internet
- Deaglio S, Morra M, Mallone R, et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol. Internet. 1998 [cited 2018 Sep 4];160:395–402. Available at http://www.ncbi.nlm.nih.gov/pubmed/9551996
- Lande R, Urbani F, Di Carlo B, et al. CD38 ligation plays a direct role in the induction of IL-1beta, IL-6, and IL-10 secretion in resting human monocytes. Cell Immunol. Internet. 2002 [cited 2018 Oct 29];220:30–38. Available at http://www.ncbi.nlm.nih.gov/pubmed/12718937
- Munoz P, Mittelbrunn M, de la Fuente H, et al. Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. Blood. Internet. 2008 [cited 2018 Sep 4];111:3653–3664. Available at http://www.ncbi.nlm.nih.gov/pubmed/18212246
- Guse AH, Da Silva CP, Berg I, et al. Regulation of calcium signalling in T lymphocytes by the second messenger cyclic ADP-ribose. Nature. Internet. 1999 [cited 2018 Sep 4];398:70–73. Available at http://www.ncbi.nlm.nih.gov/pubmed/10078531
- Allard B, Beavis PA, Darcy PK, et al. Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol. Internet. 2016 [cited 2018 Sep 4];29:7–16. Available at http://www.ncbi.nlm.nih.gov/pubmed/27209048
- de Weers M, Y-T T, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. Internet. 2011 [cited 2018 Oct 29];186:1840–1848. Available at http://www.ncbi.nlm.nih.gov/pubmed/21187443
- Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. Internet. 2015 [cited 2018 Oct 29];7:311–320. Available at http://www.ncbi.nlm.nih.gov/pubmed/25760767
- Krejcik J, Frerichs KA, Nijhof IS, et al. Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab. Clin Cancer Res. Internet. 2017 [cited 2018 Oct 29];23:7498–7511. Available at http://www.ncbi.nlm.nih.gov/pubmed/29025767
- Casneuf T, Xu XS, Adams HC, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. Internet. 2017 [cited 2018 Sep 4];1:2105–2114. Available at http://www.ncbi.nlm.nih.gov/pubmed/29296857
- Wang Y, Zhang Y, Hughes T, et al. Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells. Clin Cancer Res. Internet. 2018 [cited 2018 Sep 4];24:4006–4017. Available at http://www.ncbi.nlm.nih.gov/pubmed/29666301
- van Bommel PE, He Y, Schepel I, et al. CD20-selective inhibition of CD47-SIRPα “don’t eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. Oncoimmunology. Internet. 2018 [cited 2018 Sep 4];7:e1386361. Available at http://www.ncbi.nlm.nih.gov/pubmed/29308308
- Naicker S, Rigalou A, McEllistrim C, et al. Patient data supports the rationale of low dose cyclophosphamide to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-induced ADCP. Blood. Internet. 2017 [cited 2018 Sep 4];130: Abstract#121 [ASH 2017 59th Meeting Available at http://www.bloodjournal.org/content/130/Suppl_1/121?sso-checked=true
- van de Donk NWCJ, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. Internet. 2016 [cited 2018 Sep 4];127:681–695. Available at http://www.ncbi.nlm.nih.gov/pubmed/26631114
- Nijhof IS, Casneuf T, van Velzen J, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. Internet. 2016 [cited 2018 Sep 4];128:959–970. Available at http://www.ncbi.nlm.nih.gov/pubmed/27307294
- van de Donk NWCJ. Immunomodulatory effects of CD38-targeting antibodies. Immunol Lett. Internet. 2018 [cited 2018 Sep 4];199:16–22. Available at https://www.sciencedirect.com/science/article/abs/pii/S0165247818301470
- Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. Internet. 2011 [cited 2018 Sep 4];17:6389–6397. Available at http://www.ncbi.nlm.nih.gov/pubmed/22003066
- Sherbenou DW, Behrens CR, Su Y, et al. The development of potential antibody-based therapies for myeloma. Blood Rev. Internet. 2015 [cited 2018 Sep 4];29:81–91. Available at http://www.ncbi.nlm.nih.gov/pubmed/25294123
- de Zafra C, Balazs M, Fajardo F, et al. Preclinical characterization of AMG 424, a novel humanized T cell-recruiting bispecific anti-CD3/CD38 antibody. Blood. Internet. 2017 [cited 2018 Sep 4];130: Abstract#500 [ASH 2017 59th Meeting] Available at http://www.bloodjournal.org/content/130/Suppl_1/500?sso-checked=true
- Zou J, Chen D, Zong Y, et al. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma. Cancer Sci. Internet. 2015 cited 2018 Sep 4;106:512–521. Available at http://www.ncbi.nlm.nih.gov/pubmed/25664501
- Drent E, Groen RWJ, Noort WA, et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. Internet 2016 [cited 2018 Sep 4];101:616–625. Available at http://www.ncbi.nlm.nih.gov/pubmed/26858358
- Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. Internet. 2014 [cited 2018 Sep 4];124: Abstract#3474 [ASH 2014 56th Meeting] Available at http://www.bloodjournal.org/content/124/21/3474?sso-checked=true
- Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–1219. [cited 2017 Oct 27]. Internet
- Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. Internet 2016 [cited 2018 May 9];387:1551–1560. Available at https://www.sciencedirect.com/science/article/pii/S0140673615011204
- Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. Internet. 2016 [cited 2017 Oct 27];128:37–44. Available at http://www.bloodjournal.org/content/128/1/37?sso-checked=true
- McKeage K. Daratumumab: first global approval. Drugs. Internet. 2016 [cited 2018 Sep 4];76:275–281. Available at http://www.ncbi.nlm.nih.gov/pubmed/26729183
- Tzogani K, Penninga E, Schougaard Christiansen ML, et al. EMA review of daratumumab for the treatment of adult patients with multiple myeloma. Oncologist. 2018;23:594–602.
- Murphy MF, Dumont LJ, Greinacher A, et al. Interference of new drugs with compatibility testing for blood transfusion. N Engl J Med. Internet. 2016 [cited 2018 Sep 4];375:295–296. Available at http://www.ncbi.nlm.nih.gov/pubmed/27468082
- Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. Internet. 2015 [cited 2018 Sep 4];55:1545–1554. Available at http://www.ncbi.nlm.nih.gov/pubmed/25764134
- Bub CB, Dos RIN, Aravechia MG, et al. Transfusion management for patients taking an anti-CD38 monoclonal antibody. Rev Bras Hematol Hemoter. Internet. 2018 [cited 2018 Sep 4];40:25–29. Available at http://www.ncbi.nlm.nih.gov/pubmed/29519368
- Moreau P, van de Donk NWCJ, Miguel JS, et al. Practical considerations for the use of daratumumab, a novel CD38 monoclonal antibody, in myeloma. Drugs. Internet. 2016 [cited 2018 Sep 4];76:853–867. Available at http://www.ncbi.nlm.nih.gov/pubmed/27113582
- Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. Internet 2016 [cited 2017 Oct 26];375:1319–1331. Available at 10.1056/NEJMoa1607751
- San-Miguel J, Dimopoulos MA, Usmani S, et al. Depth of response and MRD with daratumumab plus lenalidomide and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in RRMM: POLLUX. Clin Lymphoma Myeloma Leuk. Internet. 2017 [cited 2018 Sep 5];17:e17–e18. Available at https://linkinghub.elsevier.com/retrieve/pii/S2152265017303191
- Usmani SZ, Dimopoulos MA, Belch A, et al. Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: updated analysis of pollux. Blood. Internet. 2016 [cited 2018 Sep 5];128: Abstract#1151 [ASH 2016 58th Meeting] Available at http://www.bloodjournal.org/content/128/22/1151?sso-checked=true
- Dimopoulos MA, White DJ, Benboubker L, et al. Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of pollux. Blood. Internet. 2017 [cited 2018 Oct 30];130: Abstract#739 [ASH 2017 59th Annual Meeting] Available at http://www.bloodjournal.org/content/130/Suppl_1/739
- Spencer A, Hungria VTM, Mateos M-V, et al. Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of castor. Blood. Internet 2017 [cited 2018 Sep 4];130: Abstract#Abstract #3145 [ASH 2017 59th Meeting] Available at http://www.bloodjournal.org/content/130/Suppl_1/3145?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Blood_TrendMD_0
- Bhatnagar V, Gormley NJ, Luo L, et al. FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy. Oncologist. Internet. 2017 [cited 2018 Sep 4];22:1347–1353. Available at http://www.ncbi.nlm.nih.gov/pubmed/28904172
- Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–766. [cited 2017 Oct 26]. Internet
- Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. Internet. 2017 [cited 2017 Dec 18];130:974–981. Available at http://www.ncbi.nlm.nih.gov/pubmed/28637662
- San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066.
- Lonial S, San-Miguel JF, Martínez-Lopez J, et al. Daratumumab in combination with carfilzomib and dexamethasone in patients (pts) with relapsed multiple myeloma (MMY1001): an open-label, phase 1b study. Blood. Internet. 2017 [cited 2018 Sep 5];130: Abstract#1869 [ASH 2017 59th Meeting] Available at http://www.bloodjournal.org/content/130/Suppl_1/1869?sso-checked=true
- San-Miguel J, Iida S, Blade J, et al. Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 years of age) patients with newly diagnosed multiple myeloma ineligible for transplantation (ALCYONE). HemaSpehere. Internet 2018;2: 5. [Abstract #S107-EHA 2018 23rd Congress] Available at https://learningcenter.ehaweb.org/eha/2018/stockholm/214502/jesus.san-miguel.daratumumab.plus.bortezomib-melphalan-prednisone.28vmp29.in.html
- Mateos M-V, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. Internet. 2017 [cited 2017 Dec 18]; Ahead of print-NEJMoa1714678 Available at DOI:10.1056/NEJMoa1714678
- Voorhees PM, Costa LJ, Reeves B, et al. Interim safety analysis of a phase 2 randomized study of daratumumab (Dara), lenalidomide (R), bortezomib (V), and dexamethasone (d; Dara-Rvd) Vs. rvd in patients (Pts) with newly diagnosed multiple myeloma (MM) eligible for high-dose therapy (HDT) and au. Blood. Internet. 2017 [cited 2018 Sep 4];130: Abstract#1879 [ASH 2017 59th Meeting] Available at http://www.bloodjournal.org/content/130/Suppl_1/1879
- Chari A, Usmani SZ, Krishnan A, et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): updated results from an open-label, phase 1b study. Blood. Internet. 2017 [cited 2018 Sep 4];130: Abstract#3110 [ASH 2017 59th Meeing] Available at http://www.bloodjournal.org/content/130/Suppl_1/3110/tab-e-letters?sso-checked=true
- Deckert J, Wetzel M-C, Bartle LM, et al. SAR650984, A novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. Internet. 2014 [cited 2018 Sep 4];20:4574–4583. Available at http://www.ncbi.nlm.nih.gov/pubmed/24987056
- Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. Internet. 2016 [2018 Sep 4];30:399–408. Available at http://www.ncbi.nlm.nih.gov/pubmed/26338273.
- D’Agostino M, Salvini M, Palumbo A, et al. Novel investigational drugs active as single agents in multiple myeloma. Expert Opin Investig Drugs. 2017;26:699–711. [cited 2017 Dec 14]. Internet
- Martin T, Richter J, Vij R, et al. A dose finding phase II trial of isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/refractory multiple myeloma. Blood. Internet. 2015 [cited 2018 Sep 4];126: Abstract#509 [ASH 2015 57th Meeting Available at http://www.bloodjournal.org/content/126/23/509?sso-checked=true
- Martin T, Baz R, Benson DM, et al. A Phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. Internet. 2017 [cited 2018 Sep 4];129: blood-2016-09-740787 Available at http://www.ncbi.nlm.nih.gov/pubmed/28483761
- Richardson PG, Mikhael J, Usmani SZ, et al. Updated results from a phase Ib study of isatux-imab plus pomalidomide (pom) and dexame-thasone (dex) in relapsed/refractory multiple myeloma (RRMM). Blood. Internet. 2017 [cited 2018 Sep 4];130:1887 [ASH 2017 59th Meeting] Available at http://www.bloodjournal.org/content/130/Suppl_1/1887/tab-article-info?sso-checked=true
- Richardson PG, Attal M, Campana F, et al. Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. Futur Oncol. Internet. 2018 [cited 2018 Sep 4];14:1035–1047. Available at http://www.ncbi.nlm.nih.gov/pubmed/29268619
- Endell J, Boxhammer R, Wurzenberger C, et al. The activity of MOR202, a fully human anti-CD38 antibody, is complemented by ADCP and is synergistically enhanced by lenalidomide in vitro and in vivo. Blood. Internet. 2012 [cited 2018 Sep 4];120: Abstract#4018 [ASH 2012 54th Meeting] Available at http://www.bloodjournal.org/content/120/21/4018
- Raab MS, Goldschmidt H, Agis H, et al. A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM). Am Soc Clin Oncol [ASCO] Annu Meet. Internet. 2015 [cited 2017 Dec 14]; p. Abstract 8574 Available at http://www.myelomabeacon.com/docs/asco2015/8574.pdf
- Tawara T, Hasegawa K, Sugiura Y, et al. Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol. Internet. 2008 [cited 2018 Feb 6];180:2294–2298. Available at http://www.ncbi.nlm.nih.gov/pubmed/18250438
- Raab M, Chatterjee M, Goldschmidt H, et al. MOR202 with low-dose dexamethasone (Dex) or pomalidomide/dex or lenalidomide/dex in relapsed or refractory multiple myeloma (RRMM): a phase I/IIa, multicenter, dose-escalation study. HemaSphere. Internet 2018;2: 373. (Abstract #S848, EHA 2018 23rd Congress] Available at https://learningcenter.ehaweb.org/eha/2018/stockholm/214462/marc.raab.mor202.with.low-dose.dexamethasone.28dex29.or.pomalidomide.dex.or.html
- Wang X, Dahl M, Nguyen D, et al. The anti-CD38 monoclonal antibody TAK-079 depletes antibody secreting cells from normal and SLE patients - ACR meeting abstracts. ACR/ARHP Annu Meet. Internet. 2016 [cited 2018 Sep 4]; p. Abstract #1085 Available athttps://acrabstracts.org/abstract/the-anti-cd38-monoclonal-antibody-tak-079-depletes-antibody-secreting-cells-from-normal-and-sle-patients/
- Goldmacher VS, Bourret LA, Levine BA, et al. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood. Internet. 1994 [cited 2018 Oct 29];84:3017–3025. Available at http://www.ncbi.nlm.nih.gov/pubmed/7524764
- Bolognesi A, Polito L, Farini V, et al. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia. J Biol Regul Homeost Agents. Internet. 2005 [cited 2018 Oct 29];19:145–152. Available at http://www.ncbi.nlm.nih.gov/pubmed/16602630
- Green DJ, Orgun NN, Jones JC, et al. A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer Res. Internet. 2014 [cited 2018 Sep 4];74:1179–1189. Available at http://www.ncbi.nlm.nih.gov/pubmed/24371230
- Green DJ, O’Steen S, Lin Y, et al. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood. Internet. 2018 [cited 2018 Sep 4];131:611–620. Available at http://www.ncbi.nlm.nih.gov/pubmed/29158362
- Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–847. [cited 2018 Sep 4]. Internet
- Richter JR, Landgren CO, Kauh JS, et al. Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma. J Clin Oncol. Internet 2018;36: Abstract#TPS3132 [ASCO 2018 Annual Meeting] DOI:10.1200/JCO.2018.36.15_suppl.TPS3132
- Chu SY, Miranda Y, Phung S, et al. Immunotherapy with long-lived anti-CD38 × anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human myeloma cell lines and CD38+ cells in monkeys: a potential therapy for multiple myeloma. Blood. Internet. 2014 [cited 2018 Sep 4];124: Abstract#4727 [ASH 2014 56th Meeting] Available at http://www.bloodjournal.org/content/124/21/4727?sso-checked=true
- Li T, Qi S, Unger M, et al. Immuno-targeting the multifunctional CD38 using nanobody. Sci Rep. Internet. 2016 [cited 2018 Sep 4];6:27055. Available at http://www.nature.com/articles/srep27055
- de la Puente P, Luderer MJ, Federico C, et al. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. J Control Release. Internet. 2018 [cited 2018 Sep 4];270:158–176. Available at http://www.ncbi.nlm.nih.gov/pubmed/29196043
- June CH, Sadelain M, Chimeric antigen receptor therapy. N Engl J Med. Internet 2018 [cited 2018 Sep 4];379: 64–73.
- Drent E, Themeli M, Poels R, et al. A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther. Internet. 2017 [cited 2018 Oct 29];25:1946–1958. Available at http://www.ncbi.nlm.nih.gov/pubmed/28506593
- Drent E, Poels R, Mulders MJ, et al. Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. Shiku H, editor. PLoS One [ Internet]. 2018 [cited 2018 Sep 4];13:e0197349. Available at. http://www.ncbi.nlm.nih.gov/pubmed/29847570
- Sorrento Therapeutics Inc. Sorrento’s TNK therapeutics provides progress update for its anti-CD38 and CD123 CAR-T programs for treatment of hematological malignancies [Internet]. CISION PR Newswire. 2016 [cited 2018 Sep 4]. Available at: https://www.prnewswire.com/news-releases/sorrentos-tnk-therapeutics-provides-progress-update-for-its-anti-cd38-and-cd123-car-t-programs-for-treatment-of-hematological-malignancies-300371312.html.